中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
23期
37-38
,共2页
参赭培气汤%肝癌%临床疗效%毒副反应
參赭培氣湯%肝癌%臨床療效%毒副反應
삼자배기탕%간암%림상료효%독부반응
Canzhepeiqi Soup%Liver cancer%Clinical efficacy%Adverse reaction
目的：探讨参赭培气汤联合FOLFOX4化疗治疗晚期肝癌的临床疗效及安全性。方法：选择本院近年来收治的晚期肝癌患者78例为研究对象，随机分为参赭培气汤组38例和对照组40例，对照组给予放化疗治疗，参赭培气汤组在放化疗基础上加用参赭培气汤治疗，对比分析两组患者的近期疗效及毒副反应发生情况。结果：参赭培气汤组化疗的近期总有效率显著高于对照组（P<0.05），且治疗期间毒副反应发生率明显低于对照组（P<0.05）。结论：参赭培气汤联合FOLFOX4化疗方案治疗晚期肝癌临床疗效满意，毒副反应少，安全、有效，值得临床推广应用。
目的：探討參赭培氣湯聯閤FOLFOX4化療治療晚期肝癌的臨床療效及安全性。方法：選擇本院近年來收治的晚期肝癌患者78例為研究對象，隨機分為參赭培氣湯組38例和對照組40例，對照組給予放化療治療，參赭培氣湯組在放化療基礎上加用參赭培氣湯治療，對比分析兩組患者的近期療效及毒副反應髮生情況。結果：參赭培氣湯組化療的近期總有效率顯著高于對照組（P<0.05），且治療期間毒副反應髮生率明顯低于對照組（P<0.05）。結論：參赭培氣湯聯閤FOLFOX4化療方案治療晚期肝癌臨床療效滿意，毒副反應少，安全、有效，值得臨床推廣應用。
목적：탐토삼자배기탕연합FOLFOX4화료치료만기간암적림상료효급안전성。방법：선택본원근년래수치적만기간암환자78례위연구대상，수궤분위삼자배기탕조38례화대조조40례，대조조급여방화료치료，삼자배기탕조재방화료기출상가용삼자배기탕치료，대비분석량조환자적근기료효급독부반응발생정황。결과：삼자배기탕조화료적근기총유효솔현저고우대조조（P<0.05），차치료기간독부반응발생솔명현저우대조조（P<0.05）。결론：삼자배기탕연합FOLFOX4화료방안치료만기간암림상료효만의，독부반응소，안전、유효，치득림상추엄응용。
Objective:To explore the clinical efficacy and safety of Canzhepeiqi Soup combined with FOLFOX4 chemotherapy regimens in treatment of advanced liver cancer.Method:To choose the advanced liver cancer patients in our hospital as the research object in recent years,and divided into Canzhepeiqi Soup group and control group randomly,to contrast and analyze the recent curative effect and adverse reaction.Result:The total effective rate of Canzhepeiqi Soup group was significantly higher than control group in the near future(P<0.05),and the incidence rate of adverse reaction was significantly lower than control group(P<0.05).Conclusion:Clinical efficacy of Canzhepeiqi Soup combined with FOLFOX4 chemotherapy regimens in treatment of advanced liver cancer is satisfied,and has less adverse reaction,it is safe and effective,is worthy of popularization and application.
